Log In
BCIQ
Print this Print this
 

IT1208

  Manage Alerts
Collapse Summary General Information
Company IDAC Theranostics Inc.
DescriptionHumanized anti-CD4 antibody enhanced with antibody dependent cellular cytotoxicity (ADCC) activity using Potelligent technology from Kyowa Hakko Kirin Co., Ltd.
Molecular Target CD4
Mechanism of ActionAntibody; Antibody dependent cellular cytotoxicity (ADCC)
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/16/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today